Dr Argento is a senior clinical endocrinologist at the Maryland Endocrine and Diabetes Center in Columbia, Maryland, where he serves as the Diabetes Technology Director. His practice emphasizes the implementation of advanced diabetes technology to improve the lives of those with insulin requiring diabetes. His experience is enriched by the fact that he has had T1D since 1968, and has personally used CGM since August 2006.

He co-authored multiple chapters in the American Diabetes Association 2013 book, "Putting Your Patients on the Pump," and was primary investigator for 3 published retrospective studies on clinical aspects of CGM use, one of which reported the long term results of personal CGM use in a large group of Medicare aged patients (Endocr Pract. 2014;20:1297-1302), and was first author of a T1D Exchange study on the impact of Medicare pump policies on patient care (J Diab Sci Tech 2020, Vol. 14(2) 257-261). He co-authored a November 2018 Diabetes Care commentary on the use of intermittently scanned CGM, and several other recent commentaries on practical applications of CGM and isCGM. He has presented on CGM and diabetes technology at ADA, EASD, AACE, and Diabetes Technology Society scientific sessions, and spoken to regional, national and international audiences on CGM and insulin pump use. He has represented the Endocrine Society before FDA and CMS on diabetes technology issues, and is actively engaged with and fundraises for JDRF.